So, back to Wyeth suing TEVA  in the US following Teva's submission of an AN DA for generic extended release venlafaxine capsules for infringement of three of their (Wyeth's) patents.
In other countries (eg, South Africa), the generic Effexor XR came out even earlier and one generic company, Ciplo Medpro  , are already legally manufacturing and selling extended release venlafaxine capsules under the brand name Venlor XR in that country.
Metoprolol succinate extended release is contraindicated in severe bradycardia, heart block of greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product.
In patients with heart failure, serious adverse events and adverse events leading up to discontinuation of study medication in MERIT-HF at an incidence greater then or equal to 1% in the group receiving metoprolol succinate extended release and greater than placebo by more than 0.
DETERx[TM] is a proprietary tamper resistant, extended release delivery platform that can be applied to drugs prone to abuse as well as drugs that have a narrow therapeutic window in which the inadvertent destruction of the time release system (crushing, breaking, chewing) can cause harm to a patient.
Collegium is focused on building a portfolio of pain products that incorporate its patent protected DETERx[TM] formulation platform that provides for extended release and tamper resistance.
Guanfacine extended release
was developed to allow once-daily dosing through a controlled release formulation," said Eliseo Salinas, MD, Shire EVP and Chief Scientific Officer.
Lodrane 24D utilizes Elite's proprietary extended release
technology to provide once-daily dosing of an effective, low-sedating antihistamine combined with a decongestant.
is a specialty pharmaceutical company utilizing its innovative AcuForm[TM] drug delivery technology to develop novel oral products and improved, extended release
formulations of existing oral drugs.
This financial commitment is an important resource as we develop a strong pipeline of products that will compete in large growing markets including Gabapentin GR, our extended release
formulation which is in late stage development for the treatment of post herpetic neuralgia and diabetic neuropathy.
King Pharmaceuticals and Depomed market Glumetza[TM] (metformin hydrochloride extended release
tablets), a new once-daily extended-release metformin formulation that features AcuForm[TM] drug-delivery technology, for the treatment of adults with type 2 diabetes in the United States.
In addition, positive data from our Phase II clinical trial in DPN may offer us an opportunity to leverage our growing presence in the diabetes field, currently represented by our recently-launched Glumetza product, a novel, extended release
formulation of metformin for the treatment of Type II diabetes.